Jack Tsai

Dr. Jack Tsai is an accomplished and respected industry professional with more than 15 years of biopharma oncology leadership in business development, mergers and acquisitions evaluation, marketing, and new product planning. Prior to joining NKGen, Dr. Tsai held the position of VP Business Development at Inhibrix, a clinical stage biopharma company developing novel therapeutic antibodies for oncology and orphan diseases. Previously, Dr. Tsai was the Oncology and Cell Therapy New Product Business Development Lead at Takeda Oncology and prior, held various leadership roles at Sanofi Genzyme specifically in oncology marketing. Dr. Tsai has extensive expertise in successful negotiation and execution of strategic partnerships with key biopharma partners within the oncology space, closing over $2B in licensing deals and acquisitions.

Dr. Tsai received his MD degree from Tufts University School of Medicine and currently serves as a faculty member in clinical and integrative medicine. He received his MBA from MIT Sloan School of Management and his BS degree in Molecular Genetics from the University of Rochester.